Active Biotech AB (publ) (ACTI.ST)
SEK 0.09
(4.53%)
SEK 0.09
(4.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -45.8 Million SEK | 21.96% |
| 2022 | -58.69 Million SEK | -17.66% |
| 2021 | -49.88 Million SEK | -55.32% |
| 2020 | -32.11 Million SEK | 10.95% |
| 2019 | -36.06 Million SEK | 2.2% |
| 2018 | -36.87 Million SEK | 66.1% |
| 2017 | -108.79 Million SEK | -82.59% |
| 2016 | -59.58 Million SEK | 69.21% |
| 2015 | -193.53 Million SEK | 16.41% |
| 2014 | -231.51 Million SEK | -9.16% |
| 2013 | -212.08 Million SEK | -21.18% |
| 2012 | -175.01 Million SEK | -85.1% |
| 2011 | -94.55 Million SEK | 57.23% |
| 2010 | -221.06 Million SEK | 1.3% |
| 2009 | -223.97 Million SEK | -23.34% |
| 2008 | -181.58 Million SEK | 12.58% |
| 2007 | -207.71 Million SEK | -49.24% |
| 2006 | -139.18 Million SEK | -2.78% |
| 2005 | -135.41 Million SEK | 22.28% |
| 2004 | -174.22 Million SEK | 43.36% |
| 2003 | -307.59 Million SEK | -2.91% |
| 2002 | -298.89 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -10.5 Million SEK | 16.0% |
| 2024 Q3 | -8 Million SEK | 24.53% |
| 2024 Q2 | -10.6 Million SEK | -0.95% |
| 2023 FY | -45.8 Million SEK | 21.96% |
| 2023 Q2 | -11.2 Million SEK | 0.0% |
| 2023 Q3 | -10.6 Million SEK | 5.36% |
| 2023 Q1 | -11.2 Million SEK | 23.59% |
| 2023 Q4 | -12.5 Million SEK | -17.92% |
| 2022 Q3 | -13.4 Million SEK | 10.07% |
| 2022 Q1 | -16.5 Million SEK | -2.33% |
| 2022 Q4 | -14.65 Million SEK | -9.39% |
| 2022 Q2 | -14.9 Million SEK | 9.7% |
| 2022 FY | -58.69 Million SEK | -17.66% |
| 2021 Q2 | -12.6 Million SEK | -28.57% |
| 2021 Q3 | -11.2 Million SEK | 11.11% |
| 2021 FY | -49.88 Million SEK | -55.32% |
| 2021 Q4 | -16.12 Million SEK | -43.97% |
| 2021 Q1 | -9.8 Million SEK | -142.27% |
| 2020 Q1 | -10.1 Million SEK | 10.08% |
| 2020 Q2 | -9.8 Million SEK | 2.97% |
| 2020 Q4 | -4.04 Million SEK | 50.67% |
| 2020 FY | -32.11 Million SEK | 10.95% |
| 2020 Q3 | -8.2 Million SEK | 16.33% |
| 2019 FY | -36.06 Million SEK | 2.2% |
| 2019 Q4 | -11.23 Million SEK | -20.77% |
| 2019 Q2 | -5.5 Million SEK | 32.1% |
| 2019 Q1 | -8.1 Million SEK | 8.76% |
| 2019 Q3 | -9.3 Million SEK | -69.09% |
| 2018 FY | -36.87 Million SEK | 66.1% |
| 2018 Q4 | -8.87 Million SEK | -2.05% |
| 2018 Q1 | -10.2 Million SEK | 83.05% |
| 2018 Q3 | -8.7 Million SEK | 4.4% |
| 2018 Q2 | -9.1 Million SEK | 10.78% |
| 2017 Q3 | -8.4 Million SEK | 65.57% |
| 2017 Q1 | -15.8 Million SEK | -6.87% |
| 2017 Q4 | -60.19 Million SEK | -616.58% |
| 2017 Q2 | -24.4 Million SEK | -54.43% |
| 2017 FY | -108.79 Million SEK | -82.59% |
| 2016 Q1 | -16.8 Million SEK | 58.85% |
| 2016 Q4 | -14.78 Million SEK | -19.23% |
| 2016 Q3 | -12.4 Million SEK | 20.0% |
| 2016 Q2 | -15.5 Million SEK | 7.74% |
| 2016 FY | -59.58 Million SEK | 69.21% |
| 2015 Q1 | -58 Million SEK | -1.73% |
| 2015 FY | -193.53 Million SEK | 16.41% |
| 2015 Q4 | -40.83 Million SEK | -74.49% |
| 2015 Q3 | -23.4 Million SEK | 67.23% |
| 2015 Q2 | -71.4 Million SEK | -23.1% |
| 2014 Q3 | -56.6 Million SEK | 1.91% |
| 2014 Q4 | -57.01 Million SEK | -0.73% |
| 2014 FY | -231.51 Million SEK | -9.16% |
| 2014 Q1 | -60.2 Million SEK | 26.66% |
| 2014 Q2 | -57.7 Million SEK | 4.15% |
| 2013 Q4 | -82.08 Million SEK | -381.12% |
| 2013 FY | -212.08 Million SEK | -21.18% |
| 2013 Q1 | -78 Million SEK | -78100.0% |
| 2013 Q3 | 29.2 Million SEK | 135.96% |
| 2013 Q2 | -81.2 Million SEK | -4.1% |
| 2012 Q1 | -99 Million SEK | -6.22% |
| 2012 Q4 | 100 Thousand SEK | 100.19% |
| 2012 Q3 | -51.6 Million SEK | -110.61% |
| 2012 Q2 | -24.5 Million SEK | 75.25% |
| 2012 FY | -175.01 Million SEK | -85.1% |
| 2011 FY | -94.55 Million SEK | 57.23% |
| 2011 Q1 | -69.3 Million SEK | -7.83% |
| 2011 Q2 | 147 Million SEK | 312.12% |
| 2011 Q3 | -79 Million SEK | -153.74% |
| 2011 Q4 | -93.2 Million SEK | -17.97% |
| 2010 Q3 | -48.5 Million SEK | 11.5% |
| 2010 Q2 | -54.8 Million SEK | -2.43% |
| 2010 Q4 | -64.26 Million SEK | -32.51% |
| 2010 Q1 | -53.5 Million SEK | 9.13% |
| 2010 FY | -221.06 Million SEK | 1.3% |
| 2009 Q2 | -56.4 Million SEK | 9.32% |
| 2009 Q1 | -62.2 Million SEK | 0.0% |
| 2009 Q3 | -46.5 Million SEK | 17.55% |
| 2009 FY | -223.97 Million SEK | -23.34% |
| 2009 Q4 | -58.87 Million SEK | -26.62% |
| 2008 FY | -181.58 Million SEK | 12.58% |
| 2007 FY | -207.71 Million SEK | -49.24% |
| 2006 FY | -139.18 Million SEK | -2.78% |
| 2005 FY | -135.41 Million SEK | 22.28% |
| 2004 FY | -174.22 Million SEK | 43.36% |
| 2003 FY | -307.59 Million SEK | -2.91% |
| 2002 FY | -298.89 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -257.031% |
| BioArctic AB (publ) | 229.24 Million SEK | 119.978% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -155.909% |
| CombiGene AB (publ) | -35.66 Million SEK | -28.416% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 69.839% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -179.303% |
| OncoZenge AB (publ) | -15.9 Million SEK | -188.014% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 81.576% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 90.176% |
| Mendus AB (publ) | -101.61 Million SEK | 54.93% |
| LIDDS AB (publ) | -40.2 Million SEK | -13.913% |
| Lipum AB (publ) | -37.17 Million SEK | -23.191% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 476.366% |
| Simris Alg AB (publ) | -37.3 Million SEK | -22.772% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -8.472% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -92.948% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 88.201% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 74.508% |
| Ziccum AB (publ) | -21.41 Million SEK | -113.899% |
| AcouSort AB (publ) | -17.08 Million SEK | -168.009% |
| Alzinova AB (publ) | -16.48 Million SEK | -177.913% |
| Amniotics AB (publ) | -30.87 Million SEK | -48.364% |
| Camurus AB (publ) | 431.44 Million SEK | 110.616% |
| Cantargia AB (publ) | -280.02 Million SEK | 83.644% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -117.154% |
| Genovis AB (publ.) | 61.5 Million SEK | 174.472% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 59.585% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -23.547% |
| Intervacc AB (publ) | -102.85 Million SEK | 55.47% |
| Kancera AB (publ) | -64.88 Million SEK | 29.418% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 950.353% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -277.639% |
| NextCell Pharma AB | -41.95 Million SEK | -9.152% |
| Saniona AB (publ) | -95.81 Million SEK | 52.197% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 85.271% |
| Xintela AB (publ) | -54.08 Million SEK | 15.315% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -10356.621% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -177.189% |
| Corline Biomedical AB | -1.8 Million SEK | -2431.786% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 74.246% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 19.396% |
| Aptahem AB (publ) | -11.11 Million SEK | -312.135% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 62.785% |
| Fluicell AB (publ) | -26.55 Million SEK | -72.479% |
| Biovica International AB (publ) | -124.82 Million SEK | 63.308% |
| Abliva AB (publ) | -95.5 Million SEK | 52.046% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 85.99% |
| 2cureX AB (publ) | -32.51 Million SEK | -40.845% |
| I-Tech AB | 20.2 Million SEK | 326.699% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 94.493% |
| Cyxone AB (publ) | -22.98 Million SEK | -99.226% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 49.891% |
| Biosergen AB | -27.03 Million SEK | -69.397% |
| Nanologica AB (publ) | -75.15 Million SEK | 39.061% |
| SynAct Pharma AB | -215.81 Million SEK | 78.778% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -3.963% |
| BioInvent International AB (publ) | -330.3 Million SEK | 86.134% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 81.615% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -361.228% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 58.092% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -292.19% |